CA2541903A1 - Methode de diagnostic et de traitement - Google Patents

Methode de diagnostic et de traitement Download PDF

Info

Publication number: CA2541903A1
Authority: CA; Canada
Prior art keywords: pkc; cancer; euphorbia; cells; pep005
Prior art date: 2006-04-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002541903A

Other languages

English (en)

Inventor

Steven Martin Ogbourne

Peter Gordon Parsons

Janet Lord

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Peplin Research Pty Ltd

Original Assignee

Peplin Research Pty Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-20

Filing date

2006-04-20

Publication date

2007-10-20

2006-04-20 Application filed by Peplin Research Pty Ltd filed Critical Peplin Research Pty Ltd

2006-04-20 Priority to CA002541903A priority Critical patent/CA2541903A1/fr

2007-10-20 Publication of CA2541903A1 publication Critical patent/CA2541903A1/fr

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 86
238000011282 treatment Methods 0.000 title claims abstract description 38
238000003745 diagnosis Methods 0.000 title abstract description 5
206010028980 Neoplasm Diseases 0.000 claims abstract description 147
201000011510 cancer Diseases 0.000 claims abstract description 128
230000035945 sensitivity Effects 0.000 claims abstract description 11
VDJHFHXMUKFKET-UHFFFAOYSA-N Ingenol mebutate Natural products CC1CC2C(C)(C)C2C2C=C(CO)C(O)C3(O)C(OC(=O)C(C)=CC)C(C)=CC31C2=O VDJHFHXMUKFKET-UHFFFAOYSA-N 0.000 claims description 110
VDJHFHXMUKFKET-WDUFCVPESA-N ingenol mebutate Chemical group C[C@@H]1C[C@H]2C(C)(C)[C@H]2[C@@H]2C=C(CO)[C@@H](O)[C@]3(O)[C@@H](OC(=O)C(\C)=C/C)C(C)=C[C@]31C2=O VDJHFHXMUKFKET-WDUFCVPESA-N 0.000 claims description 110
229960002993 ingenol mebutate Drugs 0.000 claims description 110
102000003923 Protein Kinase C Human genes 0.000 claims description 104
108090000315 Protein Kinase C Proteins 0.000 claims description 104
VEBVPUXQAPLADL-UHFFFAOYSA-N Ingenol Natural products C1=C(CO)C(O)C2(O)C(O)C(C)=CC32C(C)CC2C(C)(C)C2C1C3=O VEBVPUXQAPLADL-UHFFFAOYSA-N 0.000 claims description 60
VEBVPUXQAPLADL-POYOOMFHSA-N ingenol Chemical compound C1=C(CO)[C@@H](O)[C@]2(O)[C@@H](O)C(C)=C[C@]32[C@H](C)C[C@H]2C(C)(C)[C@H]2[C@H]1C3=O VEBVPUXQAPLADL-POYOOMFHSA-N 0.000 claims description 60
230000019491 signal transduction Effects 0.000 claims description 46
150000003839 salts Chemical class 0.000 claims description 38
230000000694 effects Effects 0.000 claims description 36
239000003814 drug Substances 0.000 claims description 27
230000002068 genetic effect Effects 0.000 claims description 20
239000000203 mixture Substances 0.000 claims description 20
208000025113 myeloid leukemia Diseases 0.000 claims description 17
230000002489 hematologic effect Effects 0.000 claims description 14
238000009472 formulation Methods 0.000 claims description 13
238000004519 manufacturing process Methods 0.000 claims description 8
230000001093 anti-cancer Effects 0.000 claims description 6
238000001514 detection method Methods 0.000 claims description 4
238000012216 screening Methods 0.000 claims description 4
231100000331 toxic Toxicity 0.000 claims description 3
230000002588 toxic effect Effects 0.000 claims description 3
239000002246 antineoplastic agent Substances 0.000 abstract description 23
230000001225 therapeutic effect Effects 0.000 abstract description 12
238000011394 anticancer treatment Methods 0.000 abstract description 6
238000009877 rendering Methods 0.000 abstract description 2
241000221079 Euphorbia <genus> Species 0.000 description 168
210000004027 cell Anatomy 0.000 description 166
230000006907 apoptotic process Effects 0.000 description 41
208000031261 Acute myeloid leukaemia Diseases 0.000 description 28
150000001875 compounds Chemical class 0.000 description 28
239000003795 chemical substances by application Substances 0.000 description 27
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 26
230000004069 differentiation Effects 0.000 description 20
150000007523 nucleic acids Chemical group 0.000 description 20
241000196324 Embryophyta Species 0.000 description 18
108020004707 nucleic acids Proteins 0.000 description 17
102000039446 nucleic acids Human genes 0.000 description 17
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 16
108090000623 proteins and genes Proteins 0.000 description 16
108090000397 Caspase 3 Proteins 0.000 description 15
102000003952 Caspase 3 Human genes 0.000 description 14
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 14
241001465754 Metazoa Species 0.000 description 14
229940079593 drug Drugs 0.000 description 14
229940090044 injection Drugs 0.000 description 14
239000007924 injection Substances 0.000 description 14
238000002347 injection Methods 0.000 description 14
230000004913 activation Effects 0.000 description 13
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 13
230000004044 response Effects 0.000 description 13
229930002330 retinoic acid Natural products 0.000 description 13
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
239000013543 active substance Substances 0.000 description 12
238000003556 assay Methods 0.000 description 11
238000002560 therapeutic procedure Methods 0.000 description 11
238000001890 transfection Methods 0.000 description 11
239000013598 vector Substances 0.000 description 11
240000001837 Euphorbia peplus Species 0.000 description 10
CESGKXMBHGUQTB-VONOSFMSSA-N [(1S,2S,6R,10S,11R,13S,14R,15R)-1,6,14-trihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-13-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] tetradecanoate Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(OC(=O)CCCCCCCCCCCCC)C(C)(C)[C@H]3[C@@H]21 CESGKXMBHGUQTB-VONOSFMSSA-N 0.000 description 10
238000009396 hybridization Methods 0.000 description 10
241000894007 species Species 0.000 description 10
229960003454 tamoxifen citrate Drugs 0.000 description 10
108010044467 Isoenzymes Proteins 0.000 description 9
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 9
239000003112 inhibitor Substances 0.000 description 9
238000001262 western blot Methods 0.000 description 9
244000067602 Chamaesyce hirta Species 0.000 description 8
108020004414 DNA Proteins 0.000 description 8
241000221017 Euphorbiaceae Species 0.000 description 8
108010029485 Protein Isoforms Proteins 0.000 description 8
102000001708 Protein Isoforms Human genes 0.000 description 8
150000001413 amino acids Chemical group 0.000 description 8
239000003153 chemical reaction reagent Substances 0.000 description 8
210000001167 myeloblast Anatomy 0.000 description 8
229940002612 prodrug Drugs 0.000 description 8
239000000651 prodrug Substances 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
230000005945 translocation Effects 0.000 description 8
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 7
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 7
208000032839 leukemia Diseases 0.000 description 7
230000001404 mediated effect Effects 0.000 description 7
239000002609 medium Substances 0.000 description 7
229960000485 methotrexate Drugs 0.000 description 7
239000002773 nucleotide Substances 0.000 description 7
108091033319 polynucleotide Proteins 0.000 description 7
102000040430 polynucleotide Human genes 0.000 description 7
239000002157 polynucleotide Substances 0.000 description 7
229960001603 tamoxifen Drugs 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
238000012546 transfer Methods 0.000 description 7
JHORJRSRQZDYPZ-UHFFFAOYSA-N 1,1,4,7,9-pentamethyldodecahydro-1h-2,8a-methanocyclopenta[a]cyclopropa[e][10]annulene Chemical class CC1CC2C(C)(C)C2C2CC(C)CC3CC(C)CC31C2 JHORJRSRQZDYPZ-UHFFFAOYSA-N 0.000 description 6
108010069236 Goserelin Proteins 0.000 description 6
-1 actives Substances 0.000 description 6
238000002512 chemotherapy Methods 0.000 description 6
239000003085 diluting agent Substances 0.000 description 6
229960002918 doxorubicin hydrochloride Drugs 0.000 description 6
108010048367 enhanced green fluorescent protein Proteins 0.000 description 6
229960002949 fluorouracil Drugs 0.000 description 6
239000000463 material Substances 0.000 description 6
229910052757 nitrogen Inorganic materials 0.000 description 6
125000003729 nucleotide group Chemical group 0.000 description 6
210000004940 nucleus Anatomy 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
230000004043 responsiveness Effects 0.000 description 6
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 5
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 5
108010092160 Dactinomycin Proteins 0.000 description 5
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 5
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
229930012538 Paclitaxel Natural products 0.000 description 5
241000288906 Primates Species 0.000 description 5
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
239000002253 acid Substances 0.000 description 5
238000007792 addition Methods 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
238000010171 animal model Methods 0.000 description 5
239000003242 anti bacterial agent Substances 0.000 description 5
230000000340 anti-metabolite Effects 0.000 description 5
229940100197 antimetabolite Drugs 0.000 description 5
239000002256 antimetabolite Substances 0.000 description 5
210000000481 breast Anatomy 0.000 description 5
229960004562 carboplatin Drugs 0.000 description 5
239000000969 carrier Substances 0.000 description 5
229960004397 cyclophosphamide Drugs 0.000 description 5
229960000684 cytarabine Drugs 0.000 description 5
229940127089 cytotoxic agent Drugs 0.000 description 5
229960003901 dacarbazine Drugs 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
239000000284 extract Substances 0.000 description 5
229940088597 hormone Drugs 0.000 description 5
239000005556 hormone Substances 0.000 description 5
230000006882 induction of apoptosis Effects 0.000 description 5
RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 5
229960004338 leuprorelin Drugs 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000003550 marker Substances 0.000 description 5
229960002985 medroxyprogesterone acetate Drugs 0.000 description 5
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 5
229960001924 melphalan Drugs 0.000 description 5
239000002207 metabolite Substances 0.000 description 5
229960001592 paclitaxel Drugs 0.000 description 5
229960002110 vincristine sulfate Drugs 0.000 description 5
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
108010006654 Bleomycin Proteins 0.000 description 4
208000003174 Brain Neoplasms Diseases 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 4
208000017604 Hodgkin disease Diseases 0.000 description 4
208000010747 Hodgkins lymphoma Diseases 0.000 description 4
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
206010035226 Plasma cell myeloma Diseases 0.000 description 4
208000000236 Prostatic Neoplasms Diseases 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
206010039491 Sarcoma Diseases 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 4
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 4
230000009471 action Effects 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
229940100198 alkylating agent Drugs 0.000 description 4
239000002168 alkylating agent Substances 0.000 description 4
229940088710 antibiotic agent Drugs 0.000 description 4
238000013459 approach Methods 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000001185 bone marrow Anatomy 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
210000000170 cell membrane Anatomy 0.000 description 4
229940044683 chemotherapy drug Drugs 0.000 description 4
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 4
229960004630 chlorambucil Drugs 0.000 description 4
229960004316 cisplatin Drugs 0.000 description 4
238000002648 combination therapy Methods 0.000 description 4
229960000978 cyproterone acetate Drugs 0.000 description 4
231100000433 cytotoxic Toxicity 0.000 description 4
230000001472 cytotoxic effect Effects 0.000 description 4
229960000640 dactinomycin Drugs 0.000 description 4
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
210000004700 fetal blood Anatomy 0.000 description 4
229960002074 flutamide Drugs 0.000 description 4
239000012634 fragment Substances 0.000 description 4
229960001101 ifosfamide Drugs 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000003211 malignant effect Effects 0.000 description 4
229960004961 mechlorethamine Drugs 0.000 description 4
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 4
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 4
210000000066 myeloid cell Anatomy 0.000 description 4
239000012071 phase Substances 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
230000026731 phosphorylation Effects 0.000 description 4
238000006366 phosphorylation reaction Methods 0.000 description 4
230000008569 process Effects 0.000 description 4
201000008261 skin carcinoma Diseases 0.000 description 4
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
238000005406 washing Methods 0.000 description 4
241000271566 Aves Species 0.000 description 3
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 3
102100022338 Integrin alpha-M Human genes 0.000 description 3
239000005517 L01XE01 - Imatinib Substances 0.000 description 3
108010000817 Leuprolide Proteins 0.000 description 3
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
208000034578 Multiple myelomas Diseases 0.000 description 3
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
241000700159 Rattus Species 0.000 description 3
LHHQTXPEHJNOCX-UHFFFAOYSA-N Rottlerin Natural products CC(=O)c1c(O)c(C)c(O)c(Oc2c(O)c3C=CC(C)(C)Cc3c(C(=O)C=Cc4ccccc4)c2O)c1O LHHQTXPEHJNOCX-UHFFFAOYSA-N 0.000 description 3
239000000654 additive Substances 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
239000000556 agonist Substances 0.000 description 3
229960001220 amsacrine Drugs 0.000 description 3
230000000719 anti-leukaemic effect Effects 0.000 description 3
230000000118 anti-neoplastic effect Effects 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
210000003969 blast cell Anatomy 0.000 description 3
239000000872 buffer Substances 0.000 description 3
229960002092 busulfan Drugs 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
229960005243 carmustine Drugs 0.000 description 3
230000022131 cell cycle Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000011260 co-administration Methods 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
210000000172 cytosol Anatomy 0.000 description 3
231100000135 cytotoxicity Toxicity 0.000 description 3
230000003013 cytotoxicity Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
229960003668 docetaxel Drugs 0.000 description 3
229960003265 epirubicin hydrochloride Drugs 0.000 description 3
229960005420 etoposide Drugs 0.000 description 3
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 3
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
230000012010 growth Effects 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 3
239000007943 implant Substances 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
201000001441 melanoma Diseases 0.000 description 3
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
229960004857 mitomycin Drugs 0.000 description 3
230000000394 mitotic effect Effects 0.000 description 3
229960001156 mitoxantrone Drugs 0.000 description 3
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
201000005962 mycosis fungoides Diseases 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000000861 pro-apoptotic effect Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
DEZFNHCVIZBHBI-ZHACJKMWSA-N rottlerin Chemical compound CC(=O)C1=C(O)C(C)=C(O)C(CC=2C(=C(C(=O)\C=C\C=3C=CC=CC=3)C=3OC(C)(C)C=CC=3C=2O)O)=C1O DEZFNHCVIZBHBI-ZHACJKMWSA-N 0.000 description 3
150000003384 small molecules Chemical class 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000010186 staining Methods 0.000 description 3
239000000758 substrate Substances 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
125000004149 thio group Chemical group *S* 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000035899 viability Effects 0.000 description 3
JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 3
229960004528 vincristine Drugs 0.000 description 3
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
206010067484 Adverse reaction Diseases 0.000 description 2
241000272517 Anseriformes Species 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
102000015790 Asparaginase Human genes 0.000 description 2
108010024976 Asparaginase Proteins 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
241001448862 Croton Species 0.000 description 2
MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 2
241000704053 Euphorbia lurida Species 0.000 description 2
241001553687 Euphorbia misella Species 0.000 description 2
241001553737 Euphorbia spathulata Species 0.000 description 2
241000558295 Homalanthus Species 0.000 description 2
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
238000000134 MTT assay Methods 0.000 description 2
231100000002 MTT assay Toxicity 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
108010021717 Nafarelin Proteins 0.000 description 2
108010016076 Octreotide Proteins 0.000 description 2
206010030155 Oesophageal carcinoma Diseases 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
201000000582 Retinoblastoma Diseases 0.000 description 2
239000012722 SDS sample buffer Substances 0.000 description 2
208000000453 Skin Neoplasms Diseases 0.000 description 2
206010041067 Small cell lung cancer Diseases 0.000 description 2
208000021712 Soft tissue sarcoma Diseases 0.000 description 2
208000005718 Stomach Neoplasms Diseases 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
108010050144 Triptorelin Pamoate Proteins 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
208000008383 Wilms tumor Diseases 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
208000009621 actinic keratosis Diseases 0.000 description 2
239000012190 activator Substances 0.000 description 2
230000006838 adverse reaction Effects 0.000 description 2
229930013930 alkaloid Natural products 0.000 description 2
229940098174 alkeran Drugs 0.000 description 2
229960000473 altretamine Drugs 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
229960003437 aminoglutethimide Drugs 0.000 description 2
229960002932 anastrozole Drugs 0.000 description 2
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
229940041181 antineoplastic drug Drugs 0.000 description 2
239000003101 antineoplastic hormone agonist and antagonist Substances 0.000 description 2
230000001640 apoptogenic effect Effects 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
239000011324 bead Substances 0.000 description 2
229960000997 bicalutamide Drugs 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
229960004117 capecitabine Drugs 0.000 description 2
239000002775 capsule Substances 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
230000030833 cell death Effects 0.000 description 2
230000032823 cell division Effects 0.000 description 2
230000003833 cell viability Effects 0.000 description 2
208000025997 central nervous system neoplasm Diseases 0.000 description 2
238000001311 chemical methods and process Methods 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
229940105442 cisplatin injection Drugs 0.000 description 2
229960002436 cladribine Drugs 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000000975 co-precipitation Methods 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
229960000975 daunorubicin Drugs 0.000 description 2
229960003109 daunorubicin hydrochloride Drugs 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
239000003599 detergent Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000001378 electrochemiluminescence detection Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
229940075383 etoposide injection Drugs 0.000 description 2
229960000752 etoposide phosphate Drugs 0.000 description 2
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
229960000961 floxuridine Drugs 0.000 description 2
229940081995 fluorouracil injection Drugs 0.000 description 2
229960004783 fotemustine Drugs 0.000 description 2
206010017758 gastric cancer Diseases 0.000 description 2
229960005277 gemcitabine Drugs 0.000 description 2
239000003163 gonadal steroid hormone Substances 0.000 description 2
229960002913 goserelin Drugs 0.000 description 2
UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
125000004356 hydroxy functional group Chemical group O* 0.000 description 2
229960000908 idarubicin Drugs 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
238000007654 immersion Methods 0.000 description 2
229940027941 immunoglobulin g Drugs 0.000 description 2
230000006698 induction Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000002601 intratumoral effect Effects 0.000 description 2
GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 2
238000009533 lab test Methods 0.000 description 2
229960003881 letrozole Drugs 0.000 description 2
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000011344 liquid material Substances 0.000 description 2
208000014018 liver neoplasm Diseases 0.000 description 2
244000144972 livestock Species 0.000 description 2
229960002247 lomustine Drugs 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
229960004296 megestrol acetate Drugs 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229960001428 mercaptopurine Drugs 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
229940080182 methotrexate injection Drugs 0.000 description 2
231100000782 microtubule inhibitor Toxicity 0.000 description 2
230000011278 mitosis Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
FSBTYDWUUWLHBD-UDXTWCDOSA-N nafarelin acetate hydrate Chemical compound O.CC(O)=O.C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 FSBTYDWUUWLHBD-UDXTWCDOSA-N 0.000 description 2
229930014626 natural product Natural products 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
229960002653 nilutamide Drugs 0.000 description 2
208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
201000008106 ocular cancer Diseases 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
239000008188 pellet Substances 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
210000001539 phagocyte Anatomy 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
229960004618 prednisone Drugs 0.000 description 2
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
239000000047 product Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
229960004432 raltitrexed Drugs 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
210000000664 rectum Anatomy 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000001850 reproductive effect Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
230000007017 scission Effects 0.000 description 2
230000011664 signaling Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
208000000587 small cell lung carcinoma Diseases 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
235000009518 sodium iodide Nutrition 0.000 description 2
239000012453 solvate Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
201000011549 stomach cancer Diseases 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
229960004964 temozolomide Drugs 0.000 description 2
229960001278 teniposide Drugs 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
229960001196 thiotepa Drugs 0.000 description 2
229960003087 tioguanine Drugs 0.000 description 2
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
206010044412 transitional cell carcinoma Diseases 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 2
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
229960003048 vinblastine Drugs 0.000 description 2
229960004982 vinblastine sulfate Drugs 0.000 description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
229960002066 vinorelbine Drugs 0.000 description 2
GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
229940033942 zoladex Drugs 0.000 description 2
DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
PBUUPFTVAPUWDE-UGZDLDLSSA-N 2-[[(2S,4S)-2-[bis(2-chloroethyl)amino]-2-oxo-1,3,2lambda5-oxazaphosphinan-4-yl]sulfanyl]ethanesulfonic acid Chemical compound OS(=O)(=O)CCS[C@H]1CCO[P@](=O)(N(CCCl)CCCl)N1 PBUUPFTVAPUWDE-UGZDLDLSSA-N 0.000 description 1
WDEHKPUUQDUYGZ-UHFFFAOYSA-N 2-methyl-1,3-thiazole 2H-tetrazole Chemical compound C=1N=NNN=1.CC1=NC=CS1 WDEHKPUUQDUYGZ-UHFFFAOYSA-N 0.000 description 1
XIFVTSIIYVGRHJ-UHFFFAOYSA-N 2-n,2-n,4-n,4-n,6-n-pentamethyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(N(C)C)=NC(N(C)C)=N1 XIFVTSIIYVGRHJ-UHFFFAOYSA-N 0.000 description 1
KBTLDMSFADPKFJ-UHFFFAOYSA-N 2-phenyl-1H-indole-3,4-dicarboximidamide Chemical compound N1C2=CC=CC(C(N)=N)=C2C(C(=N)N)=C1C1=CC=CC=C1 KBTLDMSFADPKFJ-UHFFFAOYSA-N 0.000 description 1
QMGUOJYZJKLOLH-UHFFFAOYSA-N 3-[1-[3-(dimethylamino)propyl]indol-3-yl]-4-(1h-indol-3-yl)pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(CCCN(C)C)C=C1C1=C(C=2C3=CC=CC=C3NC=2)C(=O)NC1=O QMGUOJYZJKLOLH-UHFFFAOYSA-N 0.000 description 1
WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
ZGMLACURZVGTPK-UHFFFAOYSA-N 5-fluoranyl-1h-pyrimidine-2,4-dione Chemical compound OC1=NC=C(F)C(O)=N1.FC1=CNC(=O)NC1=O ZGMLACURZVGTPK-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
241001249944 Abbreviata Species 0.000 description 1
241001060350 Acalypha Species 0.000 description 1
241000933112 Acidoton Species 0.000 description 1
241001300714 Actinostemon Species 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
241001303063 Adelia <angiosperm> Species 0.000 description 1
241001303039 Adenocline Species 0.000 description 1
241001300216 Adenophaedra Species 0.000 description 1
208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
241001554343 Agrostistachys Species 0.000 description 1
241001554332 Alchornea Species 0.000 description 1
241001303001 Alchorneopsis Species 0.000 description 1
241000545417 Aleurites Species 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 1
241000867852 Amanoa Species 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
241001542137 Anacampseros Species 0.000 description 1
206010061424 Anal cancer Diseases 0.000 description 1
241000867911 Andrachne Species 0.000 description 1
201000003076 Angiosarcoma Diseases 0.000 description 1
235000015072 Antidesma Nutrition 0.000 description 1
241000785806 Antidesma Species 0.000 description 1
208000007860 Anus Neoplasms Diseases 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
241001249101 Aporosa Species 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
241000310770 Argythamnia Species 0.000 description 1
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
241001300645 Astrococcus Species 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
206010003594 Ataxia telangiectasia Diseases 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
241001300062 Baliospermum Species 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
206010004272 Benign hydatidiform mole Diseases 0.000 description 1
241000558349 Bernardia Species 0.000 description 1
206010004593 Bile duct cancer Diseases 0.000 description 1
240000005220 Bischofia javanica Species 0.000 description 1
235000010893 Bischofia javanica Nutrition 0.000 description 1
DQYBRTASHMYDJG-UHFFFAOYSA-N Bisindolylmaleimide Chemical compound C1=CC=C2C(C=3C(=O)NC(C=3C=3C4=CC=CC=C4NC=3)=O)=CNC2=C1 DQYBRTASHMYDJG-UHFFFAOYSA-N 0.000 description 1
241001300032 Blachia Species 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
241001300698 Bonania Species 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010006143 Brain stem glioma Diseases 0.000 description 1
235000003351 Brassica cretica Nutrition 0.000 description 1
235000003343 Brassica rupestris Nutrition 0.000 description 1
241000219193 Brassicaceae Species 0.000 description 1
241000405421 Breynia Species 0.000 description 1
241000785605 Bridelia Species 0.000 description 1
235000004936 Bromus mango Nutrition 0.000 description 1
JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
101100184273 Caenorhabditis elegans mnk-1 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000071092 Candelabrum Species 0.000 description 1
241001300197 Caperonia Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
235000014653 Carica parviflora Nutrition 0.000 description 1
241001303011 Caryodendron Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000869021 Celianella Species 0.000 description 1
241001300690 Cephalocroton Species 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
241000366955 Chaenotheca Species 0.000 description 1
241000785810 Chaetocarpus Species 0.000 description 1
241000944318 Cheilosa Species 0.000 description 1
241001300185 Chiropetalum Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000005243 Chondrosarcoma Diseases 0.000 description 1
208000006332 Choriocarcinoma Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
241000785597 Cleistanthus Species 0.000 description 1
241001300651 Cnesmone Species 0.000 description 1
241000243321 Cnidaria Species 0.000 description 1
241001300671 Cnidoscolus Species 0.000 description 1
241000944184 Coccoceras Species 0.000 description 1
241000990192 Codiaeum Species 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
241000870753 Conceveiba Species 0.000 description 1
206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
206010052465 Congenital poikiloderma Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
241000870724 Croizatia Species 0.000 description 1
241001300103 Crotonopsis Species 0.000 description 1
102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
241001554488 Dalechampia Species 0.000 description 1
241000252212 Danio rerio Species 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
208000008334 Dermatofibrosarcoma Diseases 0.000 description 1
206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 description 1
208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 description 1
206010064581 Desmoplastic small round cell tumour Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
241000868948 Didymocistus Species 0.000 description 1
241000266013 Dimorphocalyx Species 0.000 description 1
241000867854 Discocarpus Species 0.000 description 1
241000819742 Ditaxis <mantid lacewing> Species 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
241000255601 Drosophila melanogaster Species 0.000 description 1
241001060713 Drypetes Species 0.000 description 1
102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 1
208000006402 Ductal Carcinoma Diseases 0.000 description 1
241000558350 Dysopsis Species 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
101710130332 ETS domain-containing protein Elk-4 Proteins 0.000 description 1
241001554477 Elateriospermum Species 0.000 description 1
208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
241000558344 Endospermum Species 0.000 description 1
206010014967 Ependymoma Diseases 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
241000016998 Erismanthus Species 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
241001553302 Euphorbia aaron-rossii Species 0.000 description 1
241000704034 Euphorbia acerensis Species 0.000 description 1
241000116144 Euphorbia acuta Species 0.000 description 1
241001553293 Euphorbia alta Species 0.000 description 1
241001553159 Euphorbia angusta Species 0.000 description 1
241001373717 Euphorbia anthonyi Species 0.000 description 1
241001373703 Euphorbia arabica Species 0.000 description 1
241001373446 Euphorbia arizonica Species 0.000 description 1
241001191295 Euphorbia arteagae Species 0.000 description 1
241001082383 Euphorbia baselicis Species 0.000 description 1
241000704022 Euphorbia bergeri Species 0.000 description 1
241001553254 Euphorbia bicolor Species 0.000 description 1
241001553252 Euphorbia bifurcata Species 0.000 description 1
241001553250 Euphorbia bilobata Species 0.000 description 1
241001191291 Euphorbia brachiata Species 0.000 description 1
241000093820 Euphorbia brachycera Species 0.000 description 1
241001618844 Euphorbia caesia Species 0.000 description 1
241001553233 Euphorbia calcicola Species 0.000 description 1
241001373282 Euphorbia capitellata Species 0.000 description 1
241001373278 Euphorbia carmenensis Species 0.000 description 1
241001553150 Euphorbia carunculata Species 0.000 description 1
241001599902 Euphorbia celastroides Species 0.000 description 1
241001373713 Euphorbia chamaerrhodos Species 0.000 description 1
241000210641 Euphorbia chamaesula Species 0.000 description 1
241001373256 Euphorbia cinerascens Species 0.000 description 1
241001191285 Euphorbia colorata Species 0.000 description 1
241000093825 Euphorbia commutata Species 0.000 description 1
241000210643 Euphorbia creberrima Species 0.000 description 1
241000210644 Euphorbia crenulata Species 0.000 description 1
241001599887 Euphorbia cubensis Species 0.000 description 1
244000048459 Euphorbia cyathophora Species 0.000 description 1
241001553148 Euphorbia degeneri Species 0.000 description 1
241001373268 Euphorbia deltoidea Species 0.000 description 1
241001599890 Euphorbia dentata Species 0.000 description 1
241001373244 Euphorbia dioeca Species 0.000 description 1
241000498739 Euphorbia dussii Species 0.000 description 1
241001553564 Euphorbia eanophylla Species 0.000 description 1
241001553561 Euphorbia eglandulosa Species 0.000 description 1
241001553555 Euphorbia eriantha Species 0.000 description 1
241000221085 Euphorbia esula Species 0.000 description 1
241001553525 Euphorbia exstipulata Species 0.000 description 1
241001373250 Euphorbia fendleri Species 0.000 description 1
241001373251 Euphorbia florida Species 0.000 description 1
241001373253 Euphorbia geyeri Species 0.000 description 1
241001373239 Euphorbia glyptosperma Species 0.000 description 1
241001373234 Euphorbia gracillima Species 0.000 description 1
241001553506 Euphorbia gradyi Species 0.000 description 1
241001553807 Euphorbia graminea Species 0.000 description 1
241001191151 Euphorbia guadalajarana Species 0.000 description 1
241001300734 Euphorbia guentheri Species 0.000 description 1
241001553803 Euphorbia hedyotoides Species 0.000 description 1
241000789809 Euphorbia helenae Species 0.000 description 1
241000210605 Euphorbia helleri Species 0.000 description 1
241001191145 Euphorbia hexagona Species 0.000 description 1
241001191128 Euphorbia hinkleyorum Species 0.000 description 1
241001373241 Euphorbia hooveri Species 0.000 description 1
241000072948 Euphorbia humistrata Species 0.000 description 1
244000106376 Euphorbia hypericifolia Species 0.000 description 1
241001553794 Euphorbia jaliscensis Species 0.000 description 1
241001373698 Euphorbia jejuna Species 0.000 description 1
241001553793 Euphorbia juttae Species 0.000 description 1
241000356166 Euphorbia knuthii Species 0.000 description 1
241001373338 Euphorbia lasiocarpa Species 0.000 description 1
241001373340 Euphorbia lata Species 0.000 description 1
241000498513 Euphorbia ledienii Species 0.000 description 1
241001373352 Euphorbia leucophylla Species 0.000 description 1
241001373354 Euphorbia linguiformis Species 0.000 description 1
241000355770 Euphorbia lugardae Species 0.000 description 1
241000817985 Euphorbia lupulina Species 0.000 description 1
241001191122 Euphorbia lycioides Species 0.000 description 1
241001191117 Euphorbia macropodoides Species 0.000 description 1
241001379537 Euphorbia melanadenia Species 0.000 description 1
241001373324 Euphorbia mendezii Species 0.000 description 1
241001373326 Euphorbia mertonii Species 0.000 description 1
241001191114 Euphorbia mexiae Species 0.000 description 1
241001373328 Euphorbia micromera Species 0.000 description 1
241001373330 Euphorbia missurica Species 0.000 description 1
241001373318 Euphorbia multiformis Species 0.000 description 1
241001600122 Euphorbia nutans Species 0.000 description 1
241001553675 Euphorbia oaxacana Species 0.000 description 1
241001373312 Euphorbia olowaluana Species 0.000 description 1
241001379530 Euphorbia parishii Species 0.000 description 1
241001373692 Euphorbia parryi Species 0.000 description 1
241001373304 Euphorbia pediculifera Species 0.000 description 1
241000210612 Euphorbia peplidion Species 0.000 description 1
241001373298 Euphorbia perlignea Species 0.000 description 1
241001373693 Euphorbia petrina Species 0.000 description 1
241001191102 Euphorbia pinetorum Species 0.000 description 1
241001373300 Euphorbia pionosperma Species 0.000 description 1
241001600106 Euphorbia poeppigii Species 0.000 description 1
241001373071 Euphorbia polycarpa Species 0.000 description 1
241001553145 Euphorbia polycnemoides Species 0.000 description 1
241001191099 Euphorbia polyphylla Species 0.000 description 1
241000704074 Euphorbia portulacoides Species 0.000 description 1
241000652460 Euphorbia procumbens Species 0.000 description 1
244000062608 Euphorbia prostrata Species 0.000 description 1
241001553778 Euphorbia pteroneura Species 0.000 description 1
241000704065 Euphorbia purpurea Species 0.000 description 1
241000097488 Euphorbia rapulum Species 0.000 description 1
241001373694 Euphorbia remyi Species 0.000 description 1
241001373069 Euphorbia revoluta Species 0.000 description 1
241001553755 Euphorbia robusta Species 0.000 description 1
241001177582 Euphorbia saxatilis Species 0.000 description 1
241000210614 Euphorbia schizoloba Species 0.000 description 1
241000704097 Euphorbia sclerocyathium Species 0.000 description 1
241001599919 Euphorbia sect. Cubanthus Species 0.000 description 1
241001553742 Euphorbia segoviensis Species 0.000 description 1
241001618891 Euphorbia seguieriana Species 0.000 description 1
241000244736 Euphorbia serpillifolia Species 0.000 description 1
241001373182 Euphorbia serrula Species 0.000 description 1
241001373183 Euphorbia setiloba Species 0.000 description 1
241001553558 Euphorbia sinclairiana Species 0.000 description 1
241001553739 Euphorbia sonorae Species 0.000 description 1
241001191091 Euphorbia soobyi Species 0.000 description 1
241001600080 Euphorbia stellata Species 0.000 description 1
241001553723 Euphorbia subpeltata Species 0.000 description 1
241001553722 Euphorbia succedanea Species 0.000 description 1
241000500281 Euphorbia telephioides Species 0.000 description 1
241000210615 Euphorbia tetrapora Species 0.000 description 1
244000256297 Euphorbia tirucalli Species 0.000 description 1
241001373689 Euphorbia trachysperma Species 0.000 description 1
241000210624 Euphorbia tuerckheimii Species 0.000 description 1
241001570576 Euphorbia turczaninowii Species 0.000 description 1
241000704100 Euphorbia umbellata Species 0.000 description 1
241001373162 Euphorbia umbellulata Species 0.000 description 1
241001373158 Euphorbia villifera Species 0.000 description 1
241001570573 Euphorbia whitei Species 0.000 description 1
241001191073 Euphorbia xanti Species 0.000 description 1
241000500277 Euphorbia xylopoda Species 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
241000789111 Excoecaria Species 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
201000001342 Fallopian tube cancer Diseases 0.000 description 1
208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
201000004939 Fanconi anemia Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
241000785753 Flueggea Species 0.000 description 1
VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
241001300136 Gavarretia Species 0.000 description 1
241000221018 Gelonium Species 0.000 description 1
241001301420 Givotia Species 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
241000421432 Glochidion Species 0.000 description 1
241001303044 Glycydendron Species 0.000 description 1
241000608174 Gymnadenia Species 0.000 description 1
241001300749 Gymnanthes Species 0.000 description 1
208000001258 Hemangiosarcoma Diseases 0.000 description 1
208000002250 Hematologic Neoplasms Diseases 0.000 description 1
208000033640 Hereditary breast cancer Diseases 0.000 description 1
244000043261 Hevea brasiliensis Species 0.000 description 1
241000869029 Hieronyma Species 0.000 description 1
102100033636 Histone H3.2 Human genes 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
101000866795 Homo sapiens Non-histone chromosomal protein HMG-14 Proteins 0.000 description 1
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
241000701806 Human papillomavirus Species 0.000 description 1
208000006937 Hydatidiform mole Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
241000868951 Hymenocardia Species 0.000 description 1
208000037147 Hypercalcaemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000000646 Interleukin-3 Human genes 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
206010061252 Intraocular melanoma Diseases 0.000 description 1
241000221089 Jatropha Species 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
108010021101 Lamin Type B Proteins 0.000 description 1
201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
206010023825 Laryngeal cancer Diseases 0.000 description 1
241000870766 Lasiocroton Species 0.000 description 1
208000018142 Leiomyosarcoma Diseases 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
241001303065 Leucocroton Species 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
201000011062 Li-Fraumeni syndrome Diseases 0.000 description 1
206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
206010062038 Lip neoplasm Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
206010025282 Lymphoedema Diseases 0.000 description 1
108040008097 MAP kinase activity proteins Proteins 0.000 description 1
102000019149 MAP kinase activity proteins Human genes 0.000 description 1
229940124647 MEK inhibitor Drugs 0.000 description 1
241001300746 Mabea Species 0.000 description 1
241001561070 Macaranga Species 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000004059 Male Breast Neoplasms Diseases 0.000 description 1
208000032271 Malignant tumor of penis Diseases 0.000 description 1
229930184510 Mallotus Natural products 0.000 description 1
241001060384 Mallotus <angiosperm> Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
240000007228 Mangifera indica Species 0.000 description 1
235000014826 Mangifera indica Nutrition 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
241000789133 Maprounea Species 0.000 description 1
101100514486 Medicago sativa MSK-1 gene Proteins 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
241000221024 Mercurialis Species 0.000 description 1
208000002030 Merkel cell carcinoma Diseases 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
241000558300 Micrandra Species 0.000 description 1
241000404165 Microcephala Species 0.000 description 1
244000085338 Microdesmis Species 0.000 description 1
241001300738 Microstachys Species 0.000 description 1
102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
208000003445 Mouth Neoplasms Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
208000014767 Myeloproliferative disease Diseases 0.000 description 1
LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
241000558292 Neoscortechinia Species 0.000 description 1
241001639851 Nephradenia Species 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
208000009905 Neurofibromatoses Diseases 0.000 description 1
208000004485 Nijmegen breakage syndrome Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
102100031353 Non-histone chromosomal protein HMG-14 Human genes 0.000 description 1
208000010505 Nose Neoplasms Diseases 0.000 description 1
241000870767 Omphalea Species 0.000 description 1
241001300642 Ophellantha Species 0.000 description 1
241001280335 Orbiculariae Species 0.000 description 1
206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
241000558287 Ostodes Species 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
241000602295 Oxydectes Species 0.000 description 1
241000366197 Paludicola Species 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
241000282520 Papio Species 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
241001300042 Pausandra Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
208000002471 Penile Neoplasms Diseases 0.000 description 1
206010034299 Penile cancer Diseases 0.000 description 1
241001387976 Pera Species 0.000 description 1
241001387969 Petalostigma Species 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
241000286209 Phasianidae Species 0.000 description 1
241001130943 Phyllanthus <Aves> Species 0.000 description 1
241000789129 Pimelodendron Species 0.000 description 1
241000951867 Piranhea Species 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
241001300673 Platygyna Species 0.000 description 1
241001300677 Plukenetia Species 0.000 description 1
241000870720 Podocalyx Species 0.000 description 1
101100505672 Podospora anserina grisea gene Proteins 0.000 description 1
235000014258 Polygonum bistorta Nutrition 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
208000037276 Primitive Peripheral Neuroectodermal Tumors Diseases 0.000 description 1
102100024028 Progonadoliberin-1 Human genes 0.000 description 1
108700020978 Proto-Oncogene Proteins 0.000 description 1
102000052575 Proto-Oncogene Human genes 0.000 description 1
241001301608 Pycnocoma Species 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
101710138742 Receptor-type tyrosine-protein phosphatase H Proteins 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
241000867913 Reverchonia Species 0.000 description 1
241000269423 Rhinella marina Species 0.000 description 1
241000867892 Richeria Species 0.000 description 1
241001333412 Richeriella Species 0.000 description 1
241000789127 Ricinocarpos Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
208000000791 Rothmund-Thomson syndrome Diseases 0.000 description 1
241000556257 Rupicola <angiosperm> Species 0.000 description 1
108091006629 SLC13A2 Proteins 0.000 description 1
241001300086 Sagotia Species 0.000 description 1
208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
206010061934 Salivary gland cancer Diseases 0.000 description 1
241000994241 Sapium Species 0.000 description 1
244000057114 Sapium sebiferum Species 0.000 description 1
102400000830 Saposin-B Human genes 0.000 description 1
241000785917 Savia Species 0.000 description 1
244000078613 Scirpus geniculatus Species 0.000 description 1
241001301432 Sclerocroton Species 0.000 description 1
241000867909 Securinega Species 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
241000710961 Semliki Forest virus Species 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
208000009359 Sezary Syndrome Diseases 0.000 description 1
208000021388 Sezary disease Diseases 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
241000710960 Sindbis virus Species 0.000 description 1
241001273190 Spathiostemon Species 0.000 description 1
241001354228 Spixia Species 0.000 description 1
235000009184 Spondias indica Nutrition 0.000 description 1
235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
241000789520 Strophioblachia Species 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
241000282887 Suidae Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
241001537924 Tetracoccus <angiosperm> Species 0.000 description 1
241001300663 Tetraplandra Species 0.000 description 1
241000870728 Tetrorchidium Species 0.000 description 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
208000000728 Thymus Neoplasms Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
241001300199 Thyrsanthera Species 0.000 description 1
241000566916 Tomentella Species 0.000 description 1
IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
241000870682 Trigonostemon Species 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
241000789056 Tyria Species 0.000 description 1
206010046431 Urethral cancer Diseases 0.000 description 1
206010046458 Urethral neoplasms Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000008385 Urogenital Neoplasms Diseases 0.000 description 1
102000012349 Uroplakins Human genes 0.000 description 1
108010061861 Uroplakins Proteins 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
201000005969 Uveal melanoma Diseases 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
208000014070 Vestibular schwannoma Diseases 0.000 description 1
241000863480 Vinca Species 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000004354 Vulvar Neoplasms Diseases 0.000 description 1
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
208000004064 acoustic neuroma Diseases 0.000 description 1
208000017733 acquired polycythemia vera Diseases 0.000 description 1
208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
229940060238 agrylin Drugs 0.000 description 1
108700025316 aldesleukin Proteins 0.000 description 1
229960005310 aldesleukin Drugs 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
125000005210 alkyl ammonium group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
230000004075 alteration Effects 0.000 description 1
208000008524 alveolar soft part sarcoma Diseases 0.000 description 1
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
229960003555 anagrelide hydrochloride Drugs 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
201000011165 anus cancer Diseases 0.000 description 1
230000005735 apoptotic response Effects 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
229940078010 arimidex Drugs 0.000 description 1
229940087620 aromasin Drugs 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
229960002756 azacitidine Drugs 0.000 description 1
229950011321 azaserine Drugs 0.000 description 1
150000001556 benzimidazoles Chemical class 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
229960004395 bleomycin sulfate Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229940088954 camptosar Drugs 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
208000002458 carcinoid tumor Diseases 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
201000002797 childhood leukemia Diseases 0.000 description 1
208000011654 childhood malignant neoplasm Diseases 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
208000024207 chronic leukemia Diseases 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
229920003211 cis-1,4-polyisoprene Polymers 0.000 description 1
238000005352 clarification Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004590 computer program Methods 0.000 description 1
238000004624 confocal microscopy Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
229940088547 cosmegen Drugs 0.000 description 1
201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
229940034075 cytarabine injection Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
229940104368 daunorubicin injection Drugs 0.000 description 1
229940107841 daunoxome Drugs 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
229940063223 depo-provera Drugs 0.000 description 1
231100000223 dermal penetration Toxicity 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
238000010586 diagram Methods 0.000 description 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
230000009699 differential effect Effects 0.000 description 1
125000004982 dihaloalkyl group Chemical group 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
229940120655 eloxatin Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
229960001904 epirubicin Drugs 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
229950002017 esorubicin Drugs 0.000 description 1
ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
230000003090 exacerbative effect Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
229960000255 exemestane Drugs 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
208000024519 eye neoplasm Diseases 0.000 description 1
229940043168 fareston Drugs 0.000 description 1
229940087476 femara Drugs 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
229960000390 fludarabine Drugs 0.000 description 1
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
229960005304 fludarabine phosphate Drugs 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
230000037406 food intake Effects 0.000 description 1
YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
229960002258 fulvestrant Drugs 0.000 description 1
201000010175 gallbladder cancer Diseases 0.000 description 1
229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
229940020967 gemzar Drugs 0.000 description 1
208000003884 gestational trophoblastic disease Diseases 0.000 description 1
201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
229930182480 glucuronide Natural products 0.000 description 1
150000008134 glucuronides Chemical class 0.000 description 1
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
229960003690 goserelin acetate Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000005090 green fluorescent protein Substances 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
125000004438 haloalkoxy group Chemical group 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
230000036541 health Effects 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
229940022353 herceptin Drugs 0.000 description 1
208000025581 hereditary breast carcinoma Diseases 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
125000004446 heteroarylalkyl group Chemical group 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
229940003183 hexalen Drugs 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000013537 high throughput screening Methods 0.000 description 1
201000008298 histiocytosis Diseases 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
229940088013 hycamtin Drugs 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229940096120 hydrea Drugs 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
229960001330 hydroxycarbamide Drugs 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
229960002899 hydroxyprogesterone Drugs 0.000 description 1
230000000148 hypercalcaemia Effects 0.000 description 1
208000030915 hypercalcemia disease Diseases 0.000 description 1
201000006866 hypopharynx cancer Diseases 0.000 description 1
229960001176 idarubicin hydrochloride Drugs 0.000 description 1
229960002411 imatinib Drugs 0.000 description 1
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
229960003685 imatinib mesylate Drugs 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
239000000677 immunologic agent Substances 0.000 description 1
229940124541 immunological agent Drugs 0.000 description 1
239000012133 immunoprecipitate Substances 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000007689 inspection Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229940076264 interleukin-3 Drugs 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
201000002313 intestinal cancer Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229960004768 irinotecan Drugs 0.000 description 1
229960000779 irinotecan hydrochloride Drugs 0.000 description 1
208000022013 kidney Wilms tumor Diseases 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
229940043355 kinase inhibitor Drugs 0.000 description 1
210000005053 lamin Anatomy 0.000 description 1
206010023841 laryngeal neoplasm Diseases 0.000 description 1
229940063725 leukeran Drugs 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
201000006721 lip cancer Diseases 0.000 description 1
206010024627 liposarcoma Diseases 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
238000011068 loading method Methods 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
108010078259 luprolide acetate gel depot Proteins 0.000 description 1
229940087857 lupron Drugs 0.000 description 1
208000002502 lymphedema Diseases 0.000 description 1
239000006166 lysate Substances 0.000 description 1
229950000547 mafosfamide Drugs 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
201000003175 male breast cancer Diseases 0.000 description 1
208000010907 male breast carcinoma Diseases 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
208000016847 malignant urinary system neoplasm Diseases 0.000 description 1
235000005739 manihot Nutrition 0.000 description 1
241001515942 marmosets Species 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
229940090004 megace Drugs 0.000 description 1
230000034217 membrane fusion Effects 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
239000011325 microbead Substances 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
235000010460 mustard Nutrition 0.000 description 1
230000035772 mutation Effects 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
206010028537 myelofibrosis Diseases 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
230000003039 myelosuppressive effect Effects 0.000 description 1
229940090009 myleran Drugs 0.000 description 1
229960004309 nafarelin acetate Drugs 0.000 description 1
208000037830 nasal cancer Diseases 0.000 description 1
229940086322 navelbine Drugs 0.000 description 1
201000008026 nephroblastoma Diseases 0.000 description 1
208000007538 neurilemmoma Diseases 0.000 description 1
201000004931 neurofibromatosis Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
229960005419 nitrogen Drugs 0.000 description 1
229940085033 nolvadex Drugs 0.000 description 1
210000000633 nuclear envelope Anatomy 0.000 description 1
229960002700 octreotide Drugs 0.000 description 1
201000002575 ocular melanoma Diseases 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
201000005443 oral cavity cancer Diseases 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
201000006958 oropharynx cancer Diseases 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
229960003552 other antineoplastic agent in atc Drugs 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
229960001756 oxaliplatin Drugs 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Chemical group 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
201000001219 parotid gland cancer Diseases 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical class C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
229960002340 pentostatin Drugs 0.000 description 1
FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
201000002511 pituitary cancer Diseases 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229960003171 plicamycin Drugs 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
208000037244 polycythemia vera Diseases 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229940124606 potential therapeutic agent Drugs 0.000 description 1
244000144977 poultry Species 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
208000003476 primary myelofibrosis Diseases 0.000 description 1
229960000624 procarbazine Drugs 0.000 description 1
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
229960001586 procarbazine hydrochloride Drugs 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
238000002331 protein detection Methods 0.000 description 1
239000003909 protein kinase inhibitor Substances 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
229940063222 provera Drugs 0.000 description 1
229940117820 purinethol Drugs 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
150000004492 retinoid derivatives Chemical class 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
208000013860 rhabdoid tumor of the kidney Diseases 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
229960004641 rituximab Drugs 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
229940072272 sandostatin Drugs 0.000 description 1
206010039667 schwannoma Diseases 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
239000011669 selenium Substances 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
201000002314 small intestine cancer Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000002689 soil Substances 0.000 description 1
238000007614 solvation Methods 0.000 description 1
206010062261 spinal cord neoplasm Diseases 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229940086546 synarel Drugs 0.000 description 1
206010042863 synovial sarcoma Diseases 0.000 description 1
231100000057 systemic toxicity Toxicity 0.000 description 1
FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
238000003419 tautomerization reaction Methods 0.000 description 1
229940063683 taxotere Drugs 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
201000009377 thymus cancer Diseases 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229960000303 topotecan Drugs 0.000 description 1
229960002190 topotecan hydrochloride Drugs 0.000 description 1
229960004167 toremifene citrate Drugs 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
230000014616 translation Effects 0.000 description 1
229960000575 trastuzumab Drugs 0.000 description 1
229940032510 trelstar Drugs 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
229930187845 trigonostemon Natural products 0.000 description 1
125000004385 trihaloalkyl group Chemical group 0.000 description 1
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
229960001082 trimethoprim Drugs 0.000 description 1
229960001099 trimetrexate Drugs 0.000 description 1
NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
229960004824 triptorelin Drugs 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
208000029387 trophoblastic neoplasm Diseases 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
201000004435 urinary system cancer Diseases 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
208000037965 uterine sarcoma Diseases 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
206010046885 vaginal cancer Diseases 0.000 description 1
208000013139 vaginal neoplasm Diseases 0.000 description 1
229940061389 viadur Drugs 0.000 description 1
KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
229960004355 vindesine Drugs 0.000 description 1
COFJBSXICYYSKG-FJFFLIEUSA-N vindesine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 COFJBSXICYYSKG-FJFFLIEUSA-N 0.000 description 1
229960005212 vindesine sulfate Drugs 0.000 description 1
CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
229960002166 vinorelbine tartrate Drugs 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
201000005102 vulva cancer Diseases 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940053867 xeloda Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Natural Medicines & Medicinal Plants (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Biotechnology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
General Physics & Mathematics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
Hospice & Palliative Care (AREA)
Pathology (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Alternative & Traditional Medicine (AREA)
Botany (AREA)
Medical Informatics (AREA)
Mycology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA002541903A 2006-04-20 2006-04-20 Methode de diagnostic et de traitement Abandoned CA2541903A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA002541903A CA2541903A1 (fr)	2006-04-20	2006-04-20	Methode de diagnostic et de traitement

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA002541903A CA2541903A1 (fr)	2006-04-20	2006-04-20	Methode de diagnostic et de traitement

Publications (1)

Publication Number	Publication Date
CA2541903A1 true CA2541903A1 (fr)	2007-10-20

Family

ID=38606719

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002541903A Abandoned CA2541903A1 (fr)	2006-04-20	2006-04-20	Methode de diagnostic et de traitement

Country Status (1)

Country	Link
CA (1)	CA2541903A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012085189A1 (fr) *	2010-12-22	2012-06-28	Leo Pharma A/S	Ingénol-3-acylates i
WO2012083953A1 (fr) *	2010-12-22	2012-06-28	Leo Pharma A/S	Ingénol-3-acylates iii et ingénol-3-carbamates
WO2012083954A1 (fr) *	2010-12-22	2012-06-28	Leo Pharma A/S	3-acyl-ingénols ii
CN102597778A (zh) *	2009-10-30	2012-07-18	学校法人庆应义塾	抗癌剂感受性的判定方法
RU2575349C2 (ru) *	2010-12-22	2016-02-20	Лео Лэборетериз Лимитед	Ингенол-3-ацилаты i
KR101914460B1 (ko)	2010-07-20	2018-11-05	레오 라보라토리즈 리미티드	인게놀-3-안젤레이트의 제조방법

2006
- 2006-04-20 CA CA002541903A patent/CA2541903A1/fr not_active Abandoned

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102597778B (zh) *	2009-10-30	2016-03-02	学校法人庆应义塾	抗癌剂感受性的判定方法
CN102597778A (zh) *	2009-10-30	2012-07-18	学校法人庆应义塾	抗癌剂感受性的判定方法
US9459254B2 (en)	2009-10-30	2016-10-04	Keio University	Method for determining sensitivity to an anticancer agent
EP3640236A1 (fr) *	2010-07-20	2020-04-22	Leo Laboratories Limited	Procédés de production d'ingénol-3-angélate
EP2595948B1 (fr) *	2010-07-20	2019-09-04	Leo Laboratories Limited	Procédé de production d'ingénol-3-angélate
KR101914460B1 (ko)	2010-07-20	2018-11-05	레오 라보라토리즈 리미티드	인게놀-3-안젤레이트의 제조방법
RU2572549C2 (ru) *	2010-12-22	2016-01-20	Лео Лэборетериз Лимитед	Ингенол-3-ацилаты iii и ингенол-3-карбаматы
US9388124B2 (en)	2010-12-22	2016-07-12	Leo Laboratories Limited	Ingenol-3-acylates I
US9102687B2 (en)	2010-12-22	2015-08-11	Leo Laboratories Limited	Ingenol-3-acylates III and ingenol-3-carbamates
AU2011348637B2 (en) *	2010-12-22	2015-08-20	Leo Laboratories Limited	Ingenol-3-acylates III and ingenol-3-carbamates
WO2012085189A1 (fr) *	2010-12-22	2012-06-28	Leo Pharma A/S	Ingénol-3-acylates i
RU2575349C2 (ru) *	2010-12-22	2016-02-20	Лео Лэборетериз Лимитед	Ингенол-3-ацилаты i
RU2575350C2 (ru) *	2010-12-22	2016-02-20	Лео Лэборетериз Лимитед	3-ацилингенолы ii
JP2014512331A (ja) *	2010-12-22	2014-05-22	レオ・ラボラトリーズ・リミテッド	インゲノール−３−アシラートｉｉｉおよびインゲノール−３−カルバメート
JP2016029081A (ja) *	2010-12-22	2016-03-03	レオ・ラボラトリーズ・リミテッドＬｅｏＬａｂｏｒａｔｏｒｉｅｓＬｉｍｉｔｅｄ	インゲノール−３−アシラートｉｉｉおよびインゲノール−３−カルバメート
AU2011348638B2 (en) *	2010-12-22	2015-05-21	Leo Laboratories Limited	3-acyl-ingenols II
JP2014507396A (ja) *	2010-12-22	2014-03-27	レオ・ラボラトリーズ・リミテッド	イノゲノール−３−アシラートｉ
AU2015210441B2 (en) *	2010-12-22	2016-10-06	Leo Laboratories Limited	Ingenol-3-acylates iii and ingenol-3-carbamates
US9656945B2 (en)	2010-12-22	2017-05-23	Leo Laboratories Limited	3-acyl-ingenols II
US9708286B2 (en)	2010-12-22	2017-07-18	Leo Laboratories Limited	Ingenol-3-acylates III and ingenol-3-carbamates
JP2014507393A (ja) *	2010-12-22	2014-03-27	レオ・ラボラトリーズ・リミテッド	３−アシル−イノゲノールｉｉ
WO2012083954A1 (fr) *	2010-12-22	2012-06-28	Leo Pharma A/S	3-acyl-ingénols ii
WO2012083953A1 (fr) *	2010-12-22	2012-06-28	Leo Pharma A/S	Ingénol-3-acylates iii et ingénol-3-carbamates

Publication	Publication Date	Title
Xu et al.	2018	Breast cancer susceptibility protein 1 (BRCA1) rescues neurons from cerebral ischemia/reperfusion injury through NRF2-mediated antioxidant pathway
Lee et al.	2013	Antitumor activity of methyl gallate by inhibition of focal adhesion formation and Akt phosphorylation in glioma cells
Butturini et al.	2013	Mild oxidative stress induces S-glutathionylation of STAT3 and enhances chemosensitivity of tumoural cells to chemotherapeutic drugs
Bonet-Ponce et al.	2015	On the mechanism underlying ethanol-induced mitochondrial dynamic disruption and autophagy response
Jiang et al.	2016	Anti-tumor effects of osthole on ovarian cancer cells in vitro
Peng et al.	2019	Lovastatin inhibits Toll-like receptor 4 signaling in microglia by targeting its co-receptor myeloid differentiation protein 2 and attenuates neuropathic pain
Li et al.	2015	Targeting thioredoxin-1 with siRNA exacerbates oxidative stress injury after cerebral ischemia/reperfusion in rats
CA2541903A1 (fr)	2007-10-20	Methode de diagnostic et de traitement
Zhou et al.	2019	Hydroxysafflor Yellow A mitigated myocardial ischemia/reperfusion injury by inhibiting the activation of the JAK2/STAT1 pathway
Chen et al.	2012	Urotensin II prevents cardiomyocyte apoptosis induced by doxorubicin via Akt and ERK
US20080069809A1 (en)	2008-03-20	Compositions and methods for the diagnosis and treatment of cancer
Zhang et al.	2018	Inhibiting Jumoji domain containing protein 3 (JMJD3) prevent neuronal apoptosis from stroke
Cai et al.	2019	Allicin alleviated learning and memory deficits caused by lead exposure at developmental stage
Wang et al.	2016	Total flavonoid aglycones extract in Radix scutellariae inhibits lung carcinoma and lung metastasis by affecting cell cycle and DNA synthesis
Zhang et al.	2016	Hypoxic preconditioning protects cardiomyocytes against hypoxia/reoxygenation-induced cell apoptosis via sphingosine kinase 2 and FAK/AKT pathway
Zhou et al.	2020	Hydrazinocurcumin and 5-fluorouracil enhance apoptosis and restrain tumorigenicity of HepG2 cells via disrupting the PTEN-mediated PI3K/Akt signaling pathway
Korinek et al.	2021	Randialic acid B and tomentosolic acid block formyl peptide receptor 1 in human neutrophils and attenuate psoriasis-like inflammation in vivo
Shen et al.	2021	Methyl palmitate protects heart against ischemia/reperfusion-induced injury through G-protein coupled receptor 40-mediated activation of the PI3K/AKT pathway
Xu et al.	2024	Anti-inflammatory effects of quinolinyl analog of resveratrol targeting TLR4 in MCAO/R ischemic stroke rat model
US20120302561A1 (en)	2012-11-29	Compounds, Formulations, and Methods of Protein Kinase C Inhibition
AU2006201661A1 (en)	2007-11-08	A method of diagnosis and treatment
CN101940569B (zh)	2013-02-13	含有索拉非尼和青蒿素及青蒿素类衍生物的药物组合物及其在制备治疗癌症的药物中的应用
Hu et al.	2024	Ginsenoside Rd enhances blood-brain barrier integrity after cerebral ischemia/reperfusion by alleviating endothelial cells ferroptosis via activation of NRG1/ErbB4-mediated PI3K/Akt/mTOR signaling pathway
AU2015352041B2 (en)	2018-08-23	Titled extracts of Cynara scolymus and uses thereof
Xiaoling et al.	2023	TRIM40 ameliorates diabetic retinopathy through suppressing inflammation via Reelin/DAB1 signaling disruption: A mechanism by proteasomal degradation of DAB1

Legal Events

Date	Code	Title	Description
2010-04-20	FZDE	Dead